When Wall Street Meets the Cancer Ward: Prediction Markets Now Let Traders Bet on Whether Your Clinical Trial Will Succeed

Prediction market platforms have found a controversial new frontier: allowing users to place bets on whether clinical trials will succeed or fail. Kalshi and Polymarket, platforms that facilitate billions of dollars in weekly trading volume, now offer markets on outcomes ranging from weight-loss medications to breast cancer treatments—a practice that has ignited fierce criticism from patients, researchers, and medical ethicists who warn of perverse incentives that could undermine the integrity of medical research.

Financial Incentives Meet Medical Vulnerability

The ethical concerns center on a troubling possibility: that trial personnel with access to sensitive data—pharmacists, coordinators, investigators—could manipulate trial variables to profit from prediction market positions. Critics point to numerous ways trials could be compromised, from altering infusion rates and drug storage temperatures to selectively reporting adverse events.

Joshua Pederson, a Boston University humanities professor whose son is enrolled in a pediatric cancer trial after the disease returned following an initial remission, views the practice with alarm. He argues that bettors should not be rooting for experimental medicines to fail just to earn money, calling the idea "quite ghastly." David Tsai, a clinical trial director at a San Francisco Bay Area biotech company, launched an online petition calling for a ban on such betting. Dr. Nicholas Zaorsky, a professor of radiation oncology at Mayo Clinic Jacksonville, echoed these concerns, highlighting how the financial incentives risk undermining trial integrity.

The platforms operate in a lightly regulated environment. Prediction markets have demonstrated capabilities for identifying insider traders in other contexts—helping to detect President Trump's teleprompter operator, former Congressman George Santos, and a special forces soldier betting on Venezuelan political events based on military intelligence.

Platform Defense and Safeguards

Kalshi has defended its clinical trial markets by drawing parallels to existing financial practices, comparing the betting to stock market short-selling. The company states it only offers markets on late-stage clinical trials where participants have already been selected, and currently prohibits betting on markets where all trial subjects are minors—though the policy may change in the future.

The platform claims to employ safeguards including employment verification and surveillance tools designed to detect unusual market activity. Anne Wojcicki, founder of genetic testing company 23andMe, endorsed the markets in a Kalshi-sponsored white paper, framing them as mechanisms for aggregating information about promising therapies and making clinical trials more accessible to patients.

Current betting markets include Chinese peptide approvals, weight-loss medications, and various cancer therapies, with traders wagering on FDA approval decisions.

The Human Cost Behind the Trades

For patients with limited treatment options—particularly those in pediatric oncology trials—the knowledge that others are financially incentivized for their experimental treatments to fail adds a disturbing dimension to an already difficult journey. Pederson describes how the platforms' gamified interfaces distance users from the real human cost of clinical trial outcomes. "One of the things that has struck me about these platforms is that they're flashy and they're gamified in such a way that you're often kind of distanced from the real cost," he told NPR, noting that wondering whether researchers could be motivated by prediction market profits adds to the anxieties his son already carries.

Tsai questions whether the platforms can effectively catch every potential bad actor, given the large number of people involved in clinical trials. Zaorsky emphasizes that while prediction markets can aggregate information in some settings, clinical trials are fundamentally different because investigators, coordinators, and sometimes participants can directly influence outcomes being wagered on.

The emergence of clinical trial prediction markets represents a collision between financial innovation and medical ethics, potentially eroding trust in the clinical research enterprise at a time when trial recruitment and retention already face significant challenges.

Sources

1. Kalshi and Polymarket bets on clinical trials criticized as 'ghastly' — NPR